Chief Executive Officer
Tommi is the CEO and co-founder of Blueprint Genetics, a clinical genetics company based in Helsinki, San Francisco, and Dubai. He has been running Blueprint Genetics since the beginning and is responsible for sales management, business development and financing. Tommi spends time in Bay Area regularly and is a regular speaker in life science and tech conferences in both US and Europe. Prior to Blueprint Genetics, Tommi founded a data analytics company called Whitevector and grew it to the Nordics and UK. Tommi holds a M.Sc. (Tech) from the Helsinki University of Technology where he studied business strategy and applied mathematics.
Laboratory Director, Chief Medical Officer, MD, Ph.D.
Juha is the Laboratory Director and Chief Medical Officer of Blueprint Genetics. He is a co-founder of the company as well. Juha is responsible for supervising laboratory production and for designing new diagnostic tests. On a daily basis, he participates in the clinical evaluation of genetic findings and further develops the company's variant classification and interpretation practices in collaboration with a team of geneticists. Juha has a MD-PhD from the University of Turku. In 2006, Juha completed his fellowship program in clinical physiology and nuclear medicine. The following year, he became a docent. From 2007 to 2009, he joined the UCSF Cardiac Stem Cell Translational Development Program (California, USA) as a post-doctoral researcher and later as a research specialist. He also teaches at the University of Helsinki.
Samuel is the Head of Operations at Blueprint Genetics as well as a co-founder of the company. He is an expert in genome analysis technologies and has extensive experience in bioinformatics and cancer genomics research. Samuel received his PhD from the University of Helsinki and completed his post-doctoral research at Stanford University. At Stanford, he developed high-throughput sequencing technologies such as the Oligonucleotide-Selective Sequencing (OS-Seq™). He is an adjunct professor in genetics at the University of Helsinki, an author of several high-impact publications, and an inventor in patents of DNA sequencing methods.
President, Chief Medical Officer, MD, Ph.D.
Tero-Pekka is the Chief Medical Officer, President, and a co-founder of Blueprint Genetics. He is based in San Francisco and in charge of North American operations. He designs diagnostic panels and mutation databases and works with clinical evaluation of genetic data. Tero-Pekka has a MD-PhD degree and is specialized in pediatrics and pediatric cardiology. He has a PhD in molecular and cellular biology as well. In 2007, he continued his research at Stanford University, School of Medicine. During this three year postdoctoral training, he focused on the molecular genetic mechanisms of cardiovascular diseases. He continued his cardiovascular research at the University of Helsinki as a principal investigator and the head of an academic research group.
As Chief Experience Officer, Sofia is responsible for customer experience and marketing at Blueprint Genetics. She leads client services, commercialization of ideas, communication, and marketing. Sofia has an extensive track record in marketing and brand building from consumer goods to life science. She holds a M.Sc. in economics and business administration from HANKEN School of Economics where she studied marketing and law.
Vice President of Sales EMEA
Willem Haagmans is the Vice President of Sales at Blueprint Genetics. Willem is responsible for developing and managing the commercial teams within the European, Middle East and African markets. Willem has spent almost twenty years in positions of increasing responsibility within sales, business development, and sales leadership for companies within the life-sciences and molecular diagnostics markets. He gained his experience within multi-nationals, like Roche Diagnostics, and has established and built commercial teams from scratch in a start-up environment, driving and motivating the sales team with dedication to reach their set goals.
Chief Financial Officer
As Chief Financial Officer, Riitta Pelli is responsible for Blueprint Genetics’ financial reporting, forecasting as well as strategic, long-term business planning. Riitta has over 15 years' of experience in auditing, financial management and M&A. Prior to joining the Blueprint team she was a partner in the transaction services team at PwC Finland. She holds a M.Sc. from Hanken School of Economics in Helsinki.
Jussi is the head of technology at Blueprint Genetics. He is in charge of directing and developing company's data science, AI and software technology efforts. He has a Master’s Degree in Computer Science and a PhD in Molecular Medicine. He has worked as a visiting scholar and research affiliate at the Broad Institute of MIT and Harvard, and as an Assistant Professor and Manager of Bioinformatics Center at the University of Eastern Finland. Jussi has an extensive track-record of publishing scientific publications, software and databases in the fields of genetics, bioinformatics and data science as well as experience from co-founding two life-science start-ups.
Board of directors
Hilde Furberg is an independent consultant and a professional board member. She has broad senior leadership experience, coming from her 35 years in sales, marketing, strategy and general management in Pharma/Biotech. Her experience is in different areas of specialty care, and from small to large global companies. Hilde has worked in companies like Baxter and Genzyme, she was most recently European Head of Rare Diseases for Sanofi Genzyme. In addition to working for Genzyme/Sanofi Genzyme, Hilde has since 2005 been a non-executive director, and board member of BerGenBio, Probi, Pronova, Clavis and Algeta. She is currently an industrial advisor to Investinor and board member of Calliditas, Tappin and CoB for Blueprint Genetics. Hilde holds a Master of Science from the University of Oslo (Norway).
Ville Koskenvuo is Partner at Vaaka Partners, a Finnish midmarket private equity firm. Before Vaaka Partners, he worked at EQT where he focused on European healthcare and medical device buyout investments. He has extensive experience from Boards of EQT-owned medical device companies such as CaridianBCT, Gambro, and HTL-Strefa. Ville Koskenvuo holds a M.Sc. (Tech) degree from Helsinki University of Technology.
Tuomas Kosonen is Partner at Inventure, which is a leading Finnish venture capital investor with approximately €120 million in committed equity capital. In his work at Inventure, he is focused on Nordic software and healthcare venture investments. He has a vast amount of experience from working on different boards in the Nordics and US. Tuomas Kosonen holds a M.Sc. degree in economics and law from Aalto University.
Brock Siegel, PhD, is an investor and advisor to seed-stage life science ventures, working through investment groups, including BioInflexion Point Partners, Life Science Angels, and QB3 Mission Bay Capital Fund. He currently serves on the Board of Directors of Mission Bio Inc., Rapid Diagnostek Inc., the Addario Lung Cancer Medical Institute, and on the Advisory Board of Cue Diagnostics Inc. Brock has been a senior executive with Henkel KGaA, Millipore, BioSearch, Applied Biosystems, Solexa, Illumina, Complete Genomics, Moleculo, and Zephyrus Bio. He has focused his career on bio-tool, diagnostic, and applied markets products, especially NGS sequencing and qPCR.
Christian Leikert has many years of venture capital experience with a focus on life sciences. In 2013, he joined the Creathor Venture team. He specializes in investments in the field of biotechnology. Christian Leikert started his career at Future Capital AG. He was responsible for investments of over 150 million euros in syndicated financing rounds aimed at companies in the life sciences sector. His career has been punctuated by multiple successfully completed M&As in Europe and the US. He has worked with companies, such as Ormecon Chemie, IEP, Aegis Analytical, and Ganymed Pharmaceuticals. Christian Leikert holds a master’s degree in business administration from Ludwig-Maximilian University in Munich. He currently is part of several advisory boards.
Christoph Kausch is a Founding Partner and CEO of MTIP and a Member of the Board of MTIP Management Sàrl in Luxembourg. He is an expert in strategic management and venture capital investing. Before founding MTIP, he led Syngenta’s global strategy department for several years. Prior to that, he was Managing Director at Hafiba AG, a boutique investment firm, where he remains a member of its board of directors. Christoph Kausch began his career at McKinsey & Company where he specialized in private equity and life sciences. He studied mechanical engineering at the Technical University of Munich and Massachusetts Institute of Technology. He earned a PhD in innovation and technology management from the University of St. Gallen and Harvard Business School.
Ann-Christine Sundell has 30 years of experience from the medical device industry, she has held various global positions. For 10 years she served as president for Genetic Screening, one of five strategic business areas with over 1500 employees worldwide within PerkinElmer, one of the largest Life Science companies. Ann-Christine Sundell has strategic and operational experience from areas such as Sales & Marketing, R&D, production, quality and compliance. Education: MSc Biochemistry. Other current assignments: Member of the board Blueprint Genetics Oy, Finland, Chairman of the Board of Serres Oy and member of the Board of Oy Medix, Minerva Foundation for Medical Research, Raisio Oyj, Ledil Oy, Zymonostics ApS and Revenio Group Oyj.
Risto is an Investment Manager at Pontos, a Finnish family-owned Private Equity firm. He is an expert in strategic management and his core focus at Pontos is on life sciences, well-being, and automotive industries. Before joining Pontos, Risto worked as a consultant at McKinsey with a focus on transformative consulting. He holds an M.Sc. degree from Helsinki University of Technology.
Senior Advisor, PhD
Guido Oelkers is currently the CEO of Swedish Orphan Biovitrium, a listed orphan drug company. He has extensive experience from pharmaceutical and health care companies including roles as CEO of BSN Medical, CEO of the Swedish medical device company Gambro, CEO of the specialty pharmaceutical company Invida and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group and Aventis (formerly Hoechst), where he began his career.
Senior Advisor, MD
Richard J. Wenstrup M.D. is a Board Certified Clinical and Molecular Geneticist. He served as Chief Medical Officer of Myriad Genetics for more than a decade, and also served in that capacity at Oxford Immunotec Ltd. At Myriad, he built the field and headquarters based Medical Affairs groups, and oversaw Myriad’s variant classification system for cancer predisposition genes. He created the Myriad’s Clinical Research group which executed validation and clinical utility studies for new test development, in collaboration with leading researchers in the US. He was also Professor of Human Genetics at Cincinnati Children’s Hospital, a co-founder of AssurexHealth, and in his academic career, principle investigator for multiple grants from the National Institutes of Health and the Orphan Products division of the U.S. Food and Drug Administration.
Senior Advisor, PhD
Gary Zweiger, PhD, is a business development professional, consultant, investor, and advisor in the life sciences with a focus on DNA sequencing, genetic testing, and molecular diagnostics. He has supported numerous innovative companies in developing partnerships, licensing, fundraising, M&A, market development, and strategy. He has held leadership positions in business development at Purigen Biosystems, Moleculo (sold to Illumina), Affymetrix, Life Technologies, and Agilent Technologies. He holds a BS in biological sciences and a PhD in genetics from Stanford University. He completed his post-doctoral studies at Genentech, and is the author of a popular science book on the race to sequence the human genome (Transducing the Genome, McGraw-Hill, 2001).
Senior Advisor, PhD
John Quackenbush received his PhD in theoretical physics from UCLA in 1990. Following a physics postdoc, he received a Special Emphasis Research Career Award from the National Center for Human Genome Research to work on the Human Genome Project. He spent two years at the Salk Institute and two years at Stanford University working in genomics and computational biology. In 1997, he moved to The Institute for Genomic Research (TIGR), pioneering expression analysis. He joined the Dana-Farber Cancer Institute and the Harvard School of Public Health in 2005. In 2012, he and Mick Correll founded Genospace, a precision medicine software company.
Scientific Advisor, MD, PhD
Juha Kere, MD, PhD, is professor of molecular genetics at the Karolinska Institutet in Stockholm, Sweden. His research interests are broad, including complex disorders, such as asthma, psoriasis, and dyslexia, and most recently, single-cell gene expression analysis to understand cellular functions. He has published over 400 original and review articles and served in expert and advisory roles for many organizations. Prior to moving to the Karolinska Institutet, he served as the Founding Director of the Finnish Genome Center in Helsinki.
Erik has over twenty years of experience in the medical device and pharmaceutical world. He has worked for leading companies, such as Abbott and bioMerieux. He has extensive experience in sales, marketing, management, and as head of a division including R&D. Erik is currently VP and General Manager of Global Ostomy at ConvaTec.